Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Avacincaptad pegol is a complement inhibitor sold as Izervay. It is approved for geographic atrophy secondary to age-related macular degeneration. The medicine is an RNA aptamer linked to polyethylene glycol and is given directly into the affected eye by intravitreal injection. Each treatment dose contains 2 mg in 0.1 mL.
read more about avacincaptad pegol ...Avacincaptad pegol binds to and inhibits complement protein C5. Blocking C5 reduces its cleavage into C5a and C5b and decreases formation of the membrane attack complex. Complement activity is involved in age-related macular degeneration biology, though the exact relationship between C5 inhibition and clinical outcomes in geographic atrophy is not fully established.
Avacincaptad pegol is approved for geographic atrophy secondary to age-related macular degeneration. It is administered to each affected eye by a qualified physician. The medicine is contraindicated when an ocular or periocular infection is present or when the eye has active intraocular inflammation.
The recommended dose is 2 mg in 0.1 mL injected into each affected eye once monthly, approximately every 28 days with a seven-day window before or after that interval. Each vial is for a single eye and single use. Intravitreal administration requires aseptic preparation and injection technique.
Intravitreal injections can cause endophthalmitis and retinal detachment. Avacincaptad pegol treatment is also linked with neovascular age-related macular degeneration and temporary increases in intraocular pressure. Common adverse reactions include conjunctival hemorrhage, increased eye pressure, blurred vision, punctate keratitis, and eye pain. New vision changes or eye pain need prompt evaluation.
It is approved for geographic atrophy secondary to age-related macular degeneration.
A qualified physician gives the medicine by intravitreal injection directly into each affected eye.
The labeled regimen is one injection into each affected eye once monthly, approximately every 28 days.
No. Ocular or periocular infection is a contraindication, as is active intraocular inflammation.
Clinical Review NDA 217225 - IZERVAY (avacincaptad pegol intravitreal solution). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217225Orig1s000MedR.pdf. Date Accessed September 14, 2026.
DailyMed - IZERVAY (avacincaptad pegol) injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1642fe6a-dc26-4d20-ae6e-654af744e3bd. Date Accessed September 14, 2026.
Drug Trials Snapshots: IZERVAY. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-izervay. Date Accessed September 14, 2026.
FDA Label - IZERVAY (avacincaptad pegol intravitreal solution). https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217225s004lbl.pdf. Date Accessed September 14, 2026.
IZERVAY (avacincaptad pegol intravitreal solution) Prescribing Information. https://www.astellas.com/content/dam/astellas-com/global/en/documents/izervay_pi.pdf. Date Accessed September 14, 2026.